Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200 mg (range, 50-600). Thalidomide had to be discontinued in six patients (19%) because of toxicity. In all, nine patients (29%; 95% CI, 13-45) achieved an objective response with thalidomide therapy (six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT.
Summary:
Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200 mg (range, 50-600). Thalidomide had to be discontinued in six patients (19%) because of toxicity. In all, nine patients (29%; 95% CI, achieved an objective response with thalidomide therapy (six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT. Thalidomide is effective in multiple myeloma (MM), even in patients who have been heavily pretreated or relapsed after high-dose therapy.
1,2 Extensive clinical and experimental data suggest that a potent allogeneic graft-versusmyeloma (GVM) effect can be induced against MM. [3] [4] [5] [6] [7] [8] [9] Although the use of reduced intensity conditioning (RIC) regimens as a possible less toxic alternative to standard myeloablative allogeneic stem cell transplantation (allo-SCT) may temper the frequency of transplant-related toxicities, 10-13 a significant proportion of patients, especially those who do not develop graft-versus-host disease (GVHD) may still relapse or progress after allo-SCT. 14, 15 This report describes the results of 31 patients who received thalidomide as a salvage therapy for progressive disease after allo-SCT.
Patients and methods

Study design
This was a retrospective study from nine different centers collaborating within the Intergroupe Francophone du Myelome (IFM) and the Socie´te´Franc¸aise de Greffes de Moelle et The´rapie Cellulaire (SFGM-TC). Centers were requested to report on MM patients who received thalidomide treatment after allo-SCT. In all, 31 patients treated between May 2000 and September 2003 met these eligibility criteria. Patients, disease and transplant characteristics are detailed in Table 1 . An individual administrative authorization was obtained for each patient before starting thalidomide treatment and all patients gave written informed consent. The primary aim of the study was to analyze disease response to thalidomide following allo-SCT in patients who showed evidence of progressive or residual disease. Other objectives included determining toxicity and incidence of GVHD.
Transplant procedures
All donors were HLA-A-, HLA-B-, and HLA-DR-identical siblings (except for patient No 18 who received allo-SCT from a matched unrelated donor). The majority of patients (n ¼ 28) received a RIC regimen for allo-SCT. The RIC regimen (n ¼ 24) included fludarabine, oral busulfan and different doses of ATG (Thymoglobuline; Sangstat, Lyon, France). 15 Patient management and supportive care was performed according to the standard procedures of each center. Overall, 11 patients (35%) received a bone marrow graft, whereas 20 patients (65%) received peripheral blood stem cells.
Clinical outcomes
Clinical outcomes that were collected included demographic characteristics of patients and donors, disease characteristics, acute and chronic GVHD, time to MM progression, maximum dose, toxicity, duration and response to thalidomide therapy.
Assessment of response
The response was judged on the basis of a decline in the level of paraprotein in serum or urine of at least 25, 50, 75, or 90% on two occasions. Patients with a reduction of less than 25% were considered to have had no response to therapy. Patients were considered in very good partial response (VGPR), when they could achieve at least 90% reduction in serum or urine paraproteins levels. Disease progression was defined as re-emergence of MM, or development of new extramedullary disease. 16 
Results
Patient characteristics and allo-SCT-related events are shown in Table 1 . Briefly, the median age of recipients was 54 years. In all, 12 (39%) were in refractory relapse before allo-SCT. The remaining 19 patients (61%) were in a plateau phase at time of allo-SCT. In the course of disease, 24 patients (77%) received at least one autologous stem cell transplantation. Median time between the initial diagnosis of MM and allo-SCT was 12 months. In this series, 13 patients could achieve some form of objective response after allo-SCT (PR or VGPR), nine of whom after clinical chronic GVHD. However, all but two patients (Nos 29 and 30) progressed at a median of 370 days after allo-SCT (Table 2) . Two patients out of 11 achieved PR after donor leukocyte infusions. However, they subsequently progressed again. Overall, 29 patients received thalidomide (Pharmion, France) salvage therapy in progressive disease, while two remaining patients were in stable disease. The median maximum daily dose of thalidomide was 200 mg (range, 50-600). Thalidomide was discontinued in 17 patients (55%) at a median of 101 (range, 45-327) days, because of toxicity (n ¼ 6), treatment failure as defined above (n ¼ 9), severe GVHD reactivation (n ¼ 1), or second allo-SCT (n ¼ 1; Table 2 ). No treatment-related toxic deaths were observed. As expected, peripheral neuropathy was the most important thalidomiderelated toxicity that was encountered. Although prolonged thalidomide therapy might lead to modifications in white blood counts (WBC), data related to WBC counts were not collected as part of this analysis. In all, nine patients (29%; 95% CI, 13-45%) achieved an objective disease response after instauration of thalidomide (six PR and three VGPR). Interestingly, all three patients achieving a VGPR developed concomitant de novo chronic GVHD. In contrast, one patient (N126) showed some signs of improvement of chronic GVHD signs. Another responding patient with PR (No 22) had failed to respond to thalidomide before allo-SCT. At time of last follow-up, 16 patients had died and 15 are still alive with a median overall follow-up after allo-SCT of 39 (range, 5-131) months. The majority of deaths were directly attributed to disease progression (n ¼ 12; 75% of all deaths; Table 2 ). Figure 1 shows the rates of overall survival in the whole cohort from the time of introduction of thalidomide therapy.
Discussion
Results from this study suggest that thalidomide as salvage therapy for MM in progression after allo-SCT is feasible and beneficial in a significant proportion of patients. A previous report on four patients showed that thalidomide might be efficient for extramedullary relapse of MM after allo-SCT. 17 Here, we could document an objective disease response rate of 30% that could be achieved in a group of heavily pretreated patients, comparing favorably to results obtained with thalidomide in different settings 1 or with other innovative drugs. 18 The use of RIC allo-SCT for MM is rapidly growing. However, disease progression, especially in patients who do not develop any form of GVHD remains a matter of concern.
15 Although thalidomide is classically reported to be effective in the treatment of GVHD, 19 we could observe in this series five cases of GVHD reactivation. This is in line with in vitro data highlighting a stimulatory effect of thalidomide on a wide range of cellular targets, 20 and with in vivo results where thalidomide demonstrated that not only it was not effective in preventing GVHD, but those patients on thalidomide developed a higher incidence of GVHD. 21 One major limitation of thalidomide therapy resides in its high rate of secondary effects, necessitating treatment discontinuation in a significant proportion of patients. 22 In order to evaluate the efficacy and toxicity of low doses of thalidomide in MM patients, a prospective ranging dose study is currently conducted by the IFM. Although there is no specific rationale to believe that thalidomide would not be active after allogeneic transplantation, it was interesting to see that some patients who were refractory to this drug before transplantation became sensitive post transplant.
Restoration of the function of major immune effectors after allo-SCT might be an explanation. Indeed, it has been shown that thalidomide may mediate its anti-MM effect by modulating NK cell number and function. 23 The latter is in accordance with other results showing the positive impact of thalidomide on IL-12 secretion, 20 since IL-12 can exert NK cell proliferation and activation. Figure 1 Overall survival from the initiation of thalidomide therapy.
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